Similar Items: Nonlinear mixed-effects modelling of drug-drug interactions between antiretroviral therapy and tuberculosis treatment
- Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study from the introduction of bedaquiline in South Africa National TB Programme
- Investigating permeation of anti-mycobacterial agents in Mycobacterium tuberculosis and M. tuberculosis-infected macrophages in vitro as a model for early stage tuberculosis drug discovery
- Strategies for optimising TB-HIV co-treatment in children and adolescents with drug-susceptible tuberculosis on rifampicin-based standard regimens
- Drug-drug interactions between antiretrovirals and fluconazole in HIV-infected patients
- A retrospective study of the clinical management and treatment outcomes of patients established on antiretroviral therapy who are newly diagnosed with tuberculosis in the public sector, KwaZulu-Natal
- Drug-drug interactions between antiretrovirals and bedaquiline
Author: Denti, Paolo
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- A scoping review on the use of telerehabilitation in physiotherapy in low and middle income countries
- Advancing tuberculosis treatment through pharmacometric modeling of drug exposure and biomarkers